Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02259517 · ClinicalTrials.gov registry record · NA
An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD
A NA study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT02259517 is a NA study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 38 participants.
The verdict
NCT02259517, a NA study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
Children with Attention-Deficit/Hyperactivity Disorder (ADHD) are typically treated with two types of medications with differing mechanisms of action: stimulants and non-stimulants. The stimulant Vyvanse (lisdexamfetamine, LDX), and the non-stimulant Intuniv (extended-release guanfacine, GXR), are both FDA approved treatment for ADHD. Clinical trials have shown that both medications are effective in reducing ADHD symptoms, although the neurobiological mechanisms by which Vyvanse and Intuniv produce these effects remain unknown. The aim of this study is to examine the mechanisms by which LDX and GXR reduce symptoms in patients with ADHD. MRI scanning will be used to identify treatment-related changes in brain structure and function.
Interventions
- DRUG Guanfacine
- DRUG Lisdexamfetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-09 |
| Est. Completion | 2021-11-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02259517
The ClinicalTrials.gov registry entry for NCT02259517 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Guanfacine is the first listed.
NCT02259517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02259517 about?
NCT02259517 is a clinical study titled "An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD". Children with Attention-Deficit/Hyperactivity Disorder (ADHD) are typically treated with two types of medications with differing mechanisms of action: stimulants and non-stimulants. The stimulant Vyvanse (lisdexamfetamine, LDX), and the non-stimulant Intuniv (extended-release guanfacine, GXR), are b...
What is the current status of trial NCT02259517?
This trial is currently terminated. It is a NA study. The enrollment target is 38 participants. The study started on 2014-09. Estimated completion is 2021-11-06.
What interventions are being tested in trial NCT02259517?
The interventions under investigation include: Guanfacine (DRUG), Lisdexamfetamine (DRUG).
Who is sponsoring clinical trial NCT02259517?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.